Yao Z, Jiang H, Wang F, Fan Z, Zhang Y, Mou S
J Cancer. 2024; 15(13):4205-4218.
PMID: 38947377
PMC: 11212080.
DOI: 10.7150/jca.95191.
Moes-Sosnowska J, Skupinska M, Lechowicz U, Szczepulska-Wojcik E, Skronska P, Rozy A
Int J Mol Sci. 2022; 23(18).
PMID: 36142417
PMC: 9505002.
DOI: 10.3390/ijms231810506.
Chen T, Chen J, Zhao X, Zhou J, Sheng Q, Zhu L
Am J Cancer Res. 2021; 11(5):1982-2004.
PMID: 34094665
PMC: 8167675.
Ferguson H, Smith M, Francavilla C
Cells. 2021; 10(5).
PMID: 34068954
PMC: 8156822.
DOI: 10.3390/cells10051201.
Liu Y, Cao M, Cai Y, Li X, Zhao C, Cui R
Front Cell Dev Biol. 2020; 8:95.
PMID: 32154250
PMC: 7044267.
DOI: 10.3389/fcell.2020.00095.
FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors - implications for therapy of luminal breast cancer.
Piasecka D, Braun M, Kitowska K, Mieczkowski K, Kordek R, Sadej R
J Exp Clin Cancer Res. 2019; 38(1):230.
PMID: 31142340
PMC: 6542018.
DOI: 10.1186/s13046-019-1236-6.
Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.
Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C
World J Clin Oncol. 2019; 10(3):136-148.
PMID: 30949443
PMC: 6441662.
DOI: 10.5306/wjco.v10.i3.136.
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
Brooks R, Tritchler D, Darcy K, Lankes H, Salani R, Sperduto P
Gynecol Oncol. 2019; 153(2):335-342.
PMID: 30827726
PMC: 6486855.
DOI: 10.1016/j.ygyno.2019.02.028.
Role of fibroblast growth factor receptor 4 in cancer.
Tang S, Hao Y, Yuan Y, Liu R, Chen Q
Cancer Sci. 2018; 109(10):3024-3031.
PMID: 30070748
PMC: 6172014.
DOI: 10.1111/cas.13759.
Combining Pathway Identification and Breast Cancer Survival Prediction via Screening-Network Methods.
Iuliano A, Occhipinti A, Angelini C, De Feis I, Lio P
Front Genet. 2018; 9:206.
PMID: 29963073
PMC: 6011013.
DOI: 10.3389/fgene.2018.00206.
Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth.
Yamamoto M, Nomura S, Hosoi A, Nagaoka K, Iino T, Yasuda T
Cancer Sci. 2018; 109(5):1480-1492.
PMID: 29532565
PMC: 5980194.
DOI: 10.1111/cas.13569.
2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.
Mo C, Zhang Z, Guise C, Li X, Luo J, Tu Z
ACS Med Chem Lett. 2017; 8(5):543-548.
PMID: 28523108
PMC: 5430393.
DOI: 10.1021/acsmedchemlett.7b00091.
Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.
Xiong S, Ma J, Feng F, Fu W, Shu S, Ma T
Oncotarget. 2017; 8(15):25300-25309.
PMID: 28445975
PMC: 5421931.
DOI: 10.18632/oncotarget.15811.
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy.
Musolino A, Campone M, Neven P, Denduluri N, Barrios C, Cortes J
Breast Cancer Res. 2017; 19(1):18.
PMID: 28183331
PMC: 5301372.
DOI: 10.1186/s13058-017-0807-8.
Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
Wu D, Guo M, Philips M, Qu L, Jiang L, Li J
PLoS One. 2016; 11(9):e0162491.
PMID: 27618313
PMC: 5019380.
DOI: 10.1371/journal.pone.0162491.
Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong K, Tan B, Choo H, Chung F, Hii L, Tan S
Oncotarget. 2016; 7(36):57633-57650.
PMID: 27192118
PMC: 5295378.
DOI: 10.18632/oncotarget.9328.
Deguelin-induced blockade of PI3K/protein kinase B/MAP kinase signaling in zebrafish and breast cancer cell lines is mediated by down-regulation of fibroblast growth factor receptor 4 activity.
Wu W, Hai Y, Chen L, Liu R, Han Y, Li W
Pharmacol Res Perspect. 2016; 4(2):e00212.
PMID: 27069628
PMC: 4804323.
DOI: 10.1002/prp2.212.
Emerging therapeutic targets in metastatic progression: A focus on breast cancer.
Li Z, Kang Y
Pharmacol Ther. 2016; 161:79-96.
PMID: 27000769
PMC: 4851893.
DOI: 10.1016/j.pharmthera.2016.03.003.
Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma.
Sheu M, Hsieh M, Chiang W, Yang S, Lee H, Lee L
PLoS One. 2015; 10(4):e0122961.
PMID: 25860955
PMC: 4393280.
DOI: 10.1371/journal.pone.0122961.
The Fibroblast Growth Factor signaling pathway.
Ornitz D, Itoh N
Wiley Interdiscip Rev Dev Biol. 2015; 4(3):215-66.
PMID: 25772309
PMC: 4393358.
DOI: 10.1002/wdev.176.